Home > Focus Areas > Focus on Infectious Disease > Post
  • Saved

3yr
Amiodarone for the Treatment of Arrhythmias in COVID-19 Patients Does Not Increase the Risk of Pulmonary Fibrosis: A Retrospective Cohort Study

Amiodarone for the Treatment of Arrhythmias in COVID-19 Patients Does Not Increase the Risk of Pulmonary Fibrosis: A Retrospective Cohort Study

Source : https://www.cureus.com/articles/133667-amiodarone-for-the-treatment-of-arrhythmias-in-covid-19-patients-does-not-increase-the-risk-of-pulmonary-fibrosis-a-retrospective-cohort-study

Amiodarone is a class III antiarrhythmic medication used to treat atrial and ventricular tachyarrhythmias. Pulmonary fibrosis from amiodarone use is a well-documented side effect. Pre-COVID-19 pandemic studies have shown that amiodarone-induced pulmonary fibrosis occurs in 1%-5% of patients and usually occurs between 12 to 60 months after initiation.



The clinical factors associated with the development of pulmonary fibrosis in both groups included a history of preexisting interstitial lung disease (ILD) (p=0.001), exposure to prior radiation therapy (p=0.021), and higher severity of COVID-19 illness (p

  • 3yr
    Amiodarone is a class III antiarrhythmic medication utilized in the rhythm control of both atrial and ventricular tachyarrhythmias. Its mechanism works to prolong the action potential duration by blocking potassium channels.